Cargando…
Harmonizing Optimal Strategy for Treatment of coronary artery diseases – comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial
BACKGROUND: Antiplatelet treatment is an important component in optimizing the clinical outcomes after percutaneous coronary intervention (PCI) especially in patients with acute coronary syndrome (ACS). Prasugrel, which is a new P2Y12 inhibitor, has been confirmed as efficacious in a large trial in...
Autores principales: | Lee, Joo Myung, Jung, Ji-Hyun, Park, Kyung Woo, Shin, Eun-Seok, Oh, Seok Kyu, Bae, Jang-Whan, Rhew, Jay Young, Lee, Namho, Kim, Dong-Bin, Kim, Ung, Han, Jung-Kyu, Lee, Sang Eun, Yang, Han-Mo, Kang, Hyun-Jae, Koo, Bon-Kwon, Kim, Sanghyun, Cho, Yun Kyeong, Shin, Won-Yong, Lim, Young-Hyo, Rha, Seung-Woon, Kim, Seok-Yeon, Lee, Sung Yun, Kim, Young-Dae, Chae, In-Ho, Cha, Kwang Soo, Kim, Hyo-Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570043/ https://www.ncbi.nlm.nih.gov/pubmed/26374625 http://dx.doi.org/10.1186/s13063-015-0925-5 |
Ejemplares similares
-
Real-world evidence of switching P2Y12 receptor–inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry
por: Kang, Jeehoon, et al.
Publicado: (2023) -
Prasugrel-Induced Hypersensitivity Skin Reaction
por: Kim, Soo-Han, et al.
Publicado: (2014) -
Effect of AcHERV-GmCSF as an Influenza Virus Vaccine Adjuvant
por: Choi, Hyo Jung, et al.
Publicado: (2015) -
Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study)
por: Park, Keun-Ho, et al.
Publicado: (2018) -
Thiazolidinediones (TZDs) enhance insulin secretory response via GPR40 and adenylate cyclase (AC)
por: Hwang, Mina, et al.
Publicado: (2021)